The VAV family of signal transduction molecules

Critical Reviews in Oncogenesis

Volumn 7, Issue 1-2, 1996, Pages 65-88

  Bustelo, Xosé R ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Dbl homology; hematopoiesis; oncogene; protein tyrosine kinase; receptor; SH2

Indexed keywords

PROTEIN TYROSINE KINASE;

CELL TRANSFORMATION; HEMATOPOIESIS; MITOGENESIS; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030429765     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v7.i1-2.50     Document Type: Review

References (113)

1. Adams, J. M., H. Houston, J. Allen, T. Lints, and R. Harvey:The hematopoietically expressed vav protooncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization. Oncogene, 7:611-618 (1992).
2. vav, in human hemopoietic cells. J. Biol. Chem., 267:18021-18025 (1992).
3. August, A., S. Gibson, Y. Kawakami, T. Kawakami, G. B. Mills, and B. DuPont:CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. Proc. Natl. Acad. Sci. U.S.A., 91:9347-9351 (1994).
4. Boguski, M. S., A. Bairoch, T. K. Attwood, and G. S. Michaels:Proto-vav and gene expression Nature, 358:113 (1992).
5. ryk protein tyrosine kinase: efficient phosphorylation of motifs recognized by Scr hornology 2 domains of the Src family. FEBS Lett., 367:149-152 (1995).
6. Bustelo, X. R. and M. Barbacid:Tyrosine phosphorylation of the vav protooncogene product in activated B cells. Science, 256:1196-1199 (1992).
7. Bustelo, X. R., J. F. Ledbetter, and M. Barbacid:Product of vav protooncogene defines a new class of tyrosine protein kinase substrates. Nature, 356:68-71 (1992).
8. Bustelo, X. R., S. D. Rubin, K. L. Suen, D. Carrasco, and M. Barbacid:Developmental expression of the vav protooncogene. Cell Growth Differ., 4:297-308 (1993).
9. Bustelo, X. R., K. L. Suen, K. Leftheris, C. A. Meyers, and M. Barbacid:Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene, 9:2405-2413 (1994).
10. Bustelo, X. R., K. L. Suen, W. M. Michael, G. Dreyfuss, and M. Barbacid:Association of the vav protooncogene product with poly(rC)-specific RNA-binding proteins. Mol. Cell. Biol., 15:1324-1332 (1995).
11. Castresana, J. and M. Saraste:Does Vav bind to F-actin through a CH domain? FEBS Lett., 374:149-151 (1995).
12. Cerione, R. A. and Y. Zheng:The Dbl family of oncogenes. Curr. Opin. Cell Biol., 8:216-222 (1996).
13. Chang, A. C., D. M. Desai, and A. Weiss:The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu. Rev. Immunol., 12:555-92 (1994).
14. vav, in platelets. J. Biol. Chem., 271:7544-7550 (1996).
15. Clevenger, C. V., W. Ngo, D. L. Sokol, S. M. Luger, and A. M. Gewirtz:Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleons of a T-cell line. J. Biol. Chem., 270:13246-13253 (1995).
16. Coppola, J., S. Bryant, T. Koda, D. Conway, and M. Barbacid:Mechanism of activation of the vav protooncogene. Cell Growth Differ., 2:95-105 (1991).
17. Coso, O. A., M. Chiariello, J. C. Yu, H. Teramoto, P. Crespo, N. Xu, T. Miki, and J. S. Gutkind:The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell, 81:1137-1146 (1995).
18. Crespo, P., X. R. Bustelo, D. S. Aaronson, O. A. Coso, M. Lopez-Barahona, M. Barbacid, and J. S. Gutkind:Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Oncogene, 13:455-460 (1996).
19. Crespo, P., K. E. Schuebel, A. A. Omstron, J. S. Gutkind, and X. R. Bustelo:Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav protooncogene product. Nature, 385:569-572 (1997).
20. Dorsch, M., P. D. Fan, J. Bogenberger, and S. P. Goff: TPO and IL-3 induce overlapping but distinct protein tyrosine phosphorylation in a myeloid precursor cell line. Biochem. Biophys. Res. Comm., 214:424-431 (1995).
21. Dosil, M., S. Wang, and I. R. Lemischka:Mitogenic signaling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol. Cell. Biol., 13:6572-6585 (1993).
22. Erwin, R. A., R. A. Kirken, M. G. Malabarba, W. L. Farrar, and H. Rui:Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and Son of Sevenless. Endocrinology, 136:3512-3517.
23. Evans, G. A., O. M. Z. Howard, R. Erwin, and W. L. Farrar:Interleukin-2 induces tyrosine phosphorylation of the vav protooncogene product in human T cells: lack of requirement for the tyrosine kinase Ick. Biochem. J., 294:339-342 (1993).
24. + thymocytes. Nature, 374:474-477 (1995).
25. Fryer, A. H., A. Chalmers, J. M. Connor, I. Fraser, S. Povey, A. D. Yates, J. R. Yates, and J. P. Osborne:Evidence that the gene for tuberous sclerosis is on chromosome 9. Lancet, 1:659-661 (1987).
26. Galland, F., S. Katzav, and D. Birnbaum:The products of the mcf-2 and vav protooncogenes and of the yeast gene cdc-24 share sequence similarities. Oncogene, 7:585-587 (1992).
27. Geng, Y., E. Gulbins, A. Altman, and M. Lotz:Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc. Natl. Acad. Sci. U.S.A., 91:8602-8606 (1994).
28. Gulbins, E., K. M. Coggestall, G. Baier, S. Katzav, P. Burn, and A. Altman:Tyrosine-kinase-stimulated guanine nucleotide activity of Vav in T cell activation. Science, 260:822-825 (1993).
29. Gulbins, E., C. Langlet, G. Baier, N. Bonnefoy-Berard, E. Herbert, A. Altman, and K. M. Coggeshall:Tyrosine phosphorylation and activation of Vav GDP/GTP exchange activity in antigen receptor-triggered B cells. J. Immunol., 152:2123-2129 (1994a).
30. Gulbins, E., K. M. Coggeshall, C. Langlet, G. Baier, N. Bonnefoy-Berard, P. Burn, A. Wittinghofer, S. Katzav, and A. Altman:Activation of Ras in vitro and intact fibroblasts by the Vav guanine nucleotide exchange protein. Mol. Cell. Biol., 14:906-913 (1994b).
31. Gulbins, E., K. M. Coggeshall, G. Baier, D. Telford, C. Langlet, G. Baier-Bitterlich, N. Bonnefoy-Berard, P. Burn, A. Wittinghofer, and A. Altman:Direct stimulation of Vav guanine nucleotide exchange activity for Ras by phorbol esters and diglycerides. Mol. Cell Biol., 14:4749-4758 (1994c).
32. Guoy, H., P. Debré, and G. Bismuth:The protooncogene Vav product is constitutively Lyrosine-phosphorylated in normal human immature T cells. Eur. J. Immunol., 25:3030-3034 (1995).
33. Gupta, D., Y. Jin, and R. Dziarski: Peptidoglycan induces transcription and secretion of TNF-α and activation of Lyn, extracellular signal-regulated kinase, and Rsk signal transduction proteins in mouse macrophages. J. Immunol., 155:2620-2630 (1995).
34. Henske, E. P., M. P. Short, S. Jozwiak, C. M. Bovey, S. Ramlakhan, J. L. Haines, and D. J. Kwiatkowski:Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1. Ann. Hum. Genet., 59:25-37 (1995).
35. Higuchi, T., H. Kanzaki, M. Fujimoto, H. Hatayama, H. Watanabe, M. Fukumoto, Y. Kaneko, H. Higashitsuji, M. Kishishita, T. Mori, and J. Fujita:Expression of vav protooncogene by nonhematopoietic trophoblast cells at the human uteroplacental interface. Biol. Reprod., 53:840-846 (1995).
36. 2 pathway by Fc∈R1 is not shared by a G protein-coupled receptor. J. Biol. Chem., 270:10960-10967 (1995).
37. vav/heterogeneous ribonucleoprotein K interaction. J. Biol. Chem., 269:20225-20228 (1994).
38. Hobert, O., B. Jallal, and A. Ullrich:Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol. Cell. Biol., 16:3066-3073 (1996a).
39. Hobert, O., J. W. Schilling, M. C. Beckerle, A. Ullrich, and B. Jallal:SH3 domain-dependent interaction of the protooncogene product Vav with the focal contact protein zyxin. Oncogene, 12:1577-1581 (1996b).
40. Holsinger, L. J., D. M. Spencer, D. J. Austin, S. L. Schreiber, and G. R. Crabtree:Signal transduction in T lymphocytes using a conditional allele of Sos. Proc. Natl. Acad. Sci. U.S.A., 92:9810-9814 (1995).
41. Hommel, U., M. Zurini, and M. Luyten:Solution structure of a cysteine rich domain of rat protein kinase C. Nature Struct. Biol., 1:383-387 (1994).
42. Horii, Y., J. F. Beeler, K. Sakaguchi, M. Tachibana, and T. Miki:A novel oncogene, ost, encodes a guanine nucleotide exchange factor that potentially links Rho and Rac signaling pathways. EMBO J., 13:4776-4786 (1994).
43. Huby, R. D., G. W. Carlile, and S. C. Ley:Interactions between the protein-tyrosine kinase ZAP-70, the protooncogene Vav, and tubulin in Jurkat T cells. J. Biol. Chem., 270:30241-30244 (1995).
44. Ihle, J. N., B. A. Witthuhn, F. W. Quelle, K. Yamamoto, and O. Silvennoinen:Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol., 13:369-398 (1995).
45. Inhorn, R. C., N. Carlesso, M. Durstin, D. A. Frank, and J. D. Griffin:Identification of a viability domain in the granulocyte/macrophage colony-stimulation factor receptor β-chain involving tyrosine-750. Proc. Natl. Acad. Sci. U.S.A., 92:8665-8669 (1995).
46. Jackman, J. K., D. G. Motto, Q. Sun, M. Tanemoto, C. W. Turk, G. A. Peltz, G. A. Koretzki, and P. R. Findell:Molecular cloning of SLP-76, a 76-kDa tyrosine phosphoprotein associated with Grb2 in T cells. J. Biol. Chem., 270:7029-7032 (1995).
47. Katzav, S., D. Martin-Zanca, and M. Barbacid: vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J., 8:2283-2290 (1989).
48. Katzav, S., J. L. Cleveland, H. E. Heslop, and D. Pulido:Loss of the amino-terminal helix-loop-helix domain of the vav protooncogene activates its transforming potential. Mol. Cell. Biol., 11:1912-1920 (1991).
49. Katzav, S.:Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav. Oncogene, 8:1757-1763 (1993).
50. Katzav, S., M. Sutherland, G. Packham, T. Yi, and A. Weiss:The protein tyrosine kinase ZAP-70 can associate with the SH2 domain of Proto-Vav. J. Biol. Chem., 269:32579-32445 (1994).
51. Kazanietz, M. G., X. R. Bustelo, M. Barbacid, W. Kolch, H. Mischak, G. Wong, G. R. Pettit, J. D. Bruns, and P. M. Blumberg:Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C ζ and the vav and c-raf protooncogene products. J. Biol. Chem., 269:11590-1594 (1994).
52. Keller, G., M. Kennedy, T. Papayannopoulou, and M. V. Wiles:Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol. Cell. Biol., 13:473-486 (1993).
53. Khosravi-Far, R., M. Chrzanowska-Wodnicka, P. A. Solski, A. Eva, K. Burridge, and C. J. Der:Vav and Dbl mediate transformation via Ras-independent mitogen activated protein kinase activation. Mol. Cell. Biol., 14:6848-6857 (1994).
54. Kiener, P. A., B. M. Rankin, A. L. Burkhardt, G. L. Schieven, L. K. Gilliland, R. B. Rowley, J. B. Bolen, and J. A. Ledbetter:Cross-linking of Fey receptor I (FcγRI) and receptor II (FcγRII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase. J. Biol. Chem., 268:24442-2448 (1993).
55. Koch, C. A., D. Anderson, M. F. Moran, C. Ellis, and T. Pawson:SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins. Science, 252:668-674 (1991).
56. Kon-Kozlowski, M., G. Pani, T. Pawson, and K. A. Siminovitch:The tyrosine phosphatase FTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells. J. Biol. Chem., 271:3856-3862 (1996).
57. Lee, J. M., M. Fournel, A. Veillette, and P. E. Branton:Association of CD45 with Lck and components of the Ras signaling pathway in pervanadate-treated mouse T-cell lines. Oncogene, 12:253-263 (1996).
58. Lemmon, M. A., K. M. Ferguson, and J. Schlessinger:PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface. Cell, 85:621-624 (1996).
59. Lisanti, M.P., P. E. Scherer, J. Vidugiriene, Z. Tang, A. Hermanowski-Vosatka, Y. H. Tu, R. F. Cook, and M. Sargiacomo:Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J. Cell. Biol., 126:111-126 (1994).
60. Luger, S. M., J. Ratajczak, M. Z. Ratajczak, W. I. Kuczynski, R. S. DiPaola, W. Ngo, C. V. Clevenger, and A. M. Gewirtz:A functional analysis of protooncogene Vav's role in adult human hematopoiesis. Blood, 87:1326-1334.
61. Machide, M., H. Mano, and K. Todokoro:Interleukin 3 and erythropoietin induce association of Vav with Tec kinase through Tec homology domain. Oncogene, 11:619-625 (1995).
62. Margolis, B., P. Hu, S. Katzav, W. Li, J. M. Oliver, A. Ullrich, A. Weiss, and J. Schlesinger:Tyrosine phosphorylation of vav protooncogene product containing SH2 domain and transcription factor motifs. Nature, 356:71-74 (1992).
63. Martinerie, C., L. A. Cannizzaro, C. M. Croce, K. Huebner, S. Katzav, and M. Barbacid:The human VAV protooncogene maps to chromosome region 19p12→p13.2. Hum. Genet., 86:65-68 (1990).
64. BCR/ABL. EMBO J., 14:257-265 (1995).
65. McKenney, D. W., H. Onodera, L. Gorman, T. Mimura, and D. M. Rothstein:Distinct isoforms of the CD45 protein-tyrosine phosphatase differentially regulate interleukin 2 secretion and activation signal pathways involving Vav in T cells. J. Biol. Chem., 270:24954-24954 (1995).
66. Mellentin, J. D., C. Murre, T. A. Donlon, P. S. McCaw, S. D. Smith, A. J. Carroll, M. E. McDonald, D. Baltimore, and M. L. Cleary:The gene for enhancer binding proteins E12/E47 lies at the t(1;19) breakpoint in acute leukemias. Science, 246:379-382 (1989).
67. Minden, A., A. Lin, F. X. Claret, A. Abo, and M. Karin:Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell, 81:1147-1157 (1995).
68. Miura, O., Y. Miura, N. Nakamura, F. W. Quelle, B. A. Witthuhn, J. N. Ihle, and N. Aoki:Induction of tyrosine phosphorylation of Vav and expression of Pim1 correlates with Jak-2-mediated growth signaling from the erythropoietin receptor. Blood, 84:4135-4141 (1994).
69. Mu, S. X., M. Xia, G. Elliott, J. Bogenberger, S. Swift, L. Bennett, D. L. Lappinga, R. Hecht, R. Lee, and C. J. Saris:Megakaryocyte growth and development factor and interleukin-3 induce patterns of protein-tyrosine phosphorylation that correlate with dominant differentiation over proliferation of mpl-transfected 32D cells. Blood, 86:4532-4543 (1995).
70. Nagata, Y. and K. Todokoro:Thrombopoietin induces activation of at least two distinct signaling pathways. FEBS Lett., 377:497-501 (1995).
71. Nakanishi,H., K. A. Brewer, and J. H. Exton:Activation of the (isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 268:13-16 (1993).
72. + thymocytes results in tyrosine phosphorylation of the T-cell receptor zeta chain. Nature, 341:651-454 (1989).
73. ras. J. Exp. Med., 180:1067-1076 (1994).
74. 1 phase. Science, 269:1270-1272 (1995).
75. Onodera, H., D. G. Motto, G. A. Koretzky, and D. M. Rothstein:Differential regulation of activation-induced tyrosine phosphorylation and recruitment of SLP-76 to Vav by distinct isoforms of the CD45 protein-tyrosine phosphatase. J. Biol. Chem., 271:22225-22230 (1996).
76. Ozelius, L., P. L. Kramer, C. B. Moskowitz, D. J. Kwiatkowski, M. F. Brin, S. B. Bressman, D. E. Schuback, C. T. Falk, N. Risch, D. de Leon, R. E. Burke, J. Haines, J. F. Gusella, S. Fahn, and X. O. Breakefield:Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron, 2:1427-1434 (1989).
77. Pani, G., K. D. Fisher, I. Mlinaric-Rascan, and K. A. Siminovitch:Signaling capacity of the T cell antigen receptor is negatively regulated by the FTP1C tyrosine phosphatase. J. Exp. Med., 184:839-852 (1996).
78. Pawson, T.:Protein modules and signaling networks. Nature, 373:573-580 (1995).
79. Pilz, A., K. Woodward, S. Povey, and C. Abbot:Comparative mapping of 50 human chromosome 9 loci in the laboratory mouse. Genomics, 25:139-149 (1995).
80. Platanias, L. C. and M. E. Sweet:Interferon α induces rapid tyrosine phosphorylation of the vav protooncogene product in hematopoietic cells. J. Biol. Chem., 269:3143-3146 (1994).
81. Ramos-Morales, F., B. J. Druker, and S. Fischer:Vav binds to several SH2/SH3 containing proteins in activated lymphocytes. Oncogene, 9:1917-1923 (1994).
82. Renwicki J. H. and S. D. Lawler:Genetical linkage between the ABO and nail-patella loci. Annu. Hum. Genet., 28:379-392 (1955).
83. Ridley, A. J.:Rho-related proteins: actin cytoskeleton and cell cycle. Curr. Opin. Genet. Dev., 5:24-30 (1995).
84. vav associates with the nuclear protein Ku-70. Mol. Cell. Biol., 16:37-44 (1996).
85. Sasaki, K., H. Odai, Y. Hanazono, H. Ueno, S. Ogawa, W. Y. Langdon, T. Tanaka, K. Miyagawa, K. Mitani, Y. Yazaki, and H. Hirai:TPO/c-MPL ligand induces tyrosine phosphorylation of multiple cellular proteins including protooncogehe products, Vav and c-Cbl, and ras signaling molecules. Biochem. Biophys. Res. Comm., 216:338-347 (1995).
86. Sato, S., T. Katagiri, S. Takaki, Y. Kikuchi, Y. Hitoshi, S. Yonehara, S. Tsukada, D. Kitamura, T. Watanabe, O. Witte, and K. Takatsu: IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases. J. Exp. Med., 180:2101-2111 (1994).
87. Schuebel, K. E., X. R. Bustelo, D. A. Nielsen, B. J. Song, M. Barbacid, D. Goldman, and I. J. Lee:Isolation and characterization of murine vav2, a member of the vav family of protooncogenes. Oncogene, 13:363-371 (1996).
88. Shultz, L. D., P. A. Schweitzer, T. V. Rajan, T. Yi, J. N. Ihle, R. J. Matthews, M. L. Thomas, and D. R. Beier:Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (HCPH) gene. Cell, 73:1445-1454 (1993).
89. Silvennoinen, O., H. Nishigaki, A. Kitanaka, M. Kumagai, C. Ito, F. Malavasi, Q. Lui, M. E. Conley, and D. Campana:CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-γ and phosphatidylinositol 3-kinase. J. Immunol., 156:100-107 (1996).
90. Smit, L., G. van der Horst, and J. Borst: Sos, Vav, and C3G participate in B cell receptor-induced signaling pathways and differentially associate with Shc-Grb2, Crk, and Crk-L adaptors. J. Biol. Chem., 271:8564-8569 (1996).
91. Song, J. S., J. Gomez, L. F. Stancato, and J. Rivera:Association of a p95 Vav-containing Signaling Complex with the FceRIy chain in the RBL-2H3 mast cell line. Evidence for a constitutive in vivo association of Vav with Grb2, Raf-1, and Erk-2 in an active complex. J. Biol. Chem., 271:26962-26970 (1996).
92. Songyang, Z., S. E. Shoelson, M. Chaudhuri, G. Gish, T. Pawson, W. G. Haser, F. King, T. Roberts, S. Ratnofsky, R. J. Lechleider, B. G. Neel, R. B. Birge, J. E. Fajardo, M. M. Chou, H. Hanafusa, B. Schaffhausen, and L. C. Cantley:SH2 domains recognize specific phosphopeptide sequences. Cell, 72:767-778 (1993).
93. Songyang, Z., S. E. Shoelson, J. McGlade, P. Oliver, T. Pawson, X. R. Bustelo, M. Barbacid, H. Sabe, H. Hanafusa, T. Yi, R. Rent, D. Baltimore, S. Ratnofsky, R. A. Feldman, and L. C. Cantley:Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell. Biol., 14:2777-2785 (1994).
94. Songyang, Z., K. L. Carraway III, M. J. Eck, S. C. Harrison, R. A. Feldman, M. Mohammadi, J. Schlessinger, S. R. Hubbard, D. P. Smith, C. Eng, M. J. Lorenzo, B. A. J. Ponder, B. J. Mayer, and L. Cantley:Catalytic specificity of protein tyrosine kinases is critical for selective signaling. Nature, 373:536-539 (1995).
95. Tarakhovski, A., M. Turner, S. Schaal, P. J. Mee, L. P. Duddy, K. Rajewsky, and V. L. J. Tybulewicz:Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature, 374:467-470 (1995).
96. Trask, B., A. Fertitta, M. Christensen, J. Youngblom, A. Bergmann, A. Copeland, P. de Jong, H. Mohrenweiser, A. Olsen, A. Carrano, and K. Tynan:Fluorescence in situ hybridization mapping of human chromosome 19: cytogenetic band location of 540 cosmids and 70 genes or DNA markers. Genomics, 15:133-145 (1993).
97. Uddin, S., S. Katzav, M. F. White, and L. C. Platanias:Insulin-dependent tyrosine phosphorylation of the vav protooncogene product in cells of hematopoietic origin. J. Biol. Chem., 270:7712-7716 (1995).
98. Uddin, S., A. Yetter, S. Katzav, C. Hofmann, M. F. White, and L. C. Platanias:Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav protooncogene product. Exp. Hematol., 24:622-627 (1996).
99. Van Seuningen, I., J. Ostrowski, X. R. Bustelo, P. R. Sleath, and K. Bomsztyk:The K protein domain that recruits the interleukin 1-responsive K protein kinase lies adjacent to a cluster of c-Src and Vav SH3-binding sites. Implications that K protein acts as a docking platform. J. Biol. Chem., 270:26976-26985 (1995).
100. Weng, W. K., L. Jarvis, and T. W. LeBien:Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidlylinositol 3-kinase complex in human B cell precursors. J. Biol. Chem., 269:32514-32514(1994).
101. Whitehead, I., H. Kirk, C. Tognon, G. Trigo-Gonzalez, and R. Kay:Expression cloning of lfc, a novel oncogene with structural similarities to guanine nucleotide exchange factors and to the regulatory region of protein kinase C. J. Biol. Chem., 270:18388-18395 (1995).
102. Winder, S. J., L. Hemmings, S. K. Maciver, S. J. Bolton, J. M. Tinsley, K. E. Davis, D. R. Critchley, and J. Kendrick-Jones:Utrophin actin binding domain: analysis of actin binding and cellular targeting. J. Cell. Sci., 108:63-71 (1995).
103. vav activity. Mol. Cell. Biol., 15:4337-4346 (1995).
104. Wu, J., D. G. Motto, G. A. Koretzky, and A. Weiss:Vav and SLP-76 interact and functionally cooperate in IL-2 gene activation. Immunity, 4:593-602 (1996).
105. Wulf, G. M., C. N. Adra, and B. Lim:Inhibition of hematopoietic development from embryonic stem cells by antisense vav mRNA. EMBO J., 12:5065-5074 (1993).
106. Xu, X. L. and S. F. Chong:Vav in natural killer cells is tyrosine phosphorylated upon cross-linking of FcγRIIIA and is constitutively associated with a serine/threonine kinase. Biochem. J., 1030:527-533.
107. Ye, Z. S. and D. Baltimore:Binding of Vav to Grb-2 through dimerization of Src homology 3 domains. Proc. Natl. Acad. Sci. U.S.A., 91:12629-12633 (1994).
108. Yuo, A., S. Kitagawa, S. Iki, M. Yagisawa, E. K. Inuo, T. Mimura, S. Minoda, Y. Hanazono, H. Hirai, A. Urabe, A. Miwa, A. Togawa, and F. Takaku:Tyrosine phosphorylation of vav protooncogene product in primary human myeologenous leukemic cells stimulated by granulocyte colony-stimulating factor. Biochem. Biphys. Res. Commun., 211:677-685 (1995).
109. -/- mouse embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A., 91:12755-12759 (1994).
110. Zhang, G., M. G. Kazanietz, P. M. Blumberg, and J. H. Hurley:Crystal structure of the Cys2 activators-binding domain of protein kinase C δ in complex with phorbol ester. Cell, 81:917-924 (1995a).
111. Zhang, R., F. W. Alt, L. Davidson, S. H. Orkin, and W. Swat:Defective signaling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav protooncogene. Nature, 374:470-473 (1995b).
112. Zheng, Y, D. Zangrilli, R. A. Cerione, and A. Eva:The pleckstrin homology domain mediates transformation by oncogenic dbl through specific intracellular targeting. J. Biol. Chem., 271:19017-19020 (1996).
113. Zmuidzinas, A., K. D. Fischer, S. Lira, L. Forrester, S. Bryant, A. Bernstein, and M. Barbacid:The vav protooncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J., 14:1-11 (1995).